News und Analysen
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q2 2024 Earnings CallAug 05, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Why Axsome Therapeutics Stock Is Sinking Today
Shares of Axsome Therapeutics (NASDAQ: AXSM) were sinking 7.5% as of 11:24 a.m. ET on Monday. And while many stocks were tumbling due to the Bank of Japan's interest rate hike, that wasn't the main
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
When it comes to investing in the right companies for your portfolio, you need to ensure you select businesses that you understand and have the competitive advantages, financials, and leadership to
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
When it comes to investing in the right companies for your portfolio, you need to ensure you select businesses that you understand and have the competitive advantages, financials, and leadership to
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
When it comes to investing in the right companies for your portfolio, you need to ensure you select businesses that you understand and have the competitive advantages, financials, and leadership to
EQS-News: MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
EQS-News: MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
3 Unstoppable Stocks to Buy in August
What are the best stocks? Usually, the ones that have clear paths to success.
Three Motley Fool contributors have identified what they believe are unstoppable stocks to buy in August. And they all
Is Regeneron Pharmaceuticals Due for a Stock Split?
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price
Is Regeneron Pharmaceuticals Due for a Stock Split?
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price
Is Regeneron Pharmaceuticals Due for a Stock Split?
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
There are plenty of excellent reasons to invest in dividend stocks, including the fact that only rock-solid companies can afford to sustain payout increases for a long time. When you put your money
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
Few healthcare companies are more famous than Johnson & Johnson (NYSE: JNJ). The pharmaceutical giant earned its stature in the industry thanks to its incredible innovative abilities and a business
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
Few healthcare companies are more famous than Johnson & Johnson (NYSE: JNJ). The pharmaceutical giant earned its stature in the industry thanks to its incredible innovative abilities and a business
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
Few healthcare companies are more famous than Johnson & Johnson (NYSE: JNJ). The pharmaceutical giant earned its stature in the industry thanks to its incredible innovative abilities and a business
Where Will Novavax Be in 5 Years?
Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in
Is This Decision by Pfizer Bad News for Eli Lilly?
Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro
Is This Decision by Pfizer Bad News for Eli Lilly?
Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
The biotech Amgen (NASDAQ: AMGN) isn't exactly known as a growth stock. Over the past few years, the company's organic revenue hasn't been increasing at a particularly impressive rate. The drugmaker
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
The biotech Amgen (NASDAQ: AMGN) isn't exactly known as a growth stock. Over the past few years, the company's organic revenue hasn't been increasing at a particularly impressive rate. The drugmaker
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
The biotech Amgen (NASDAQ: AMGN) isn't exactly known as a growth stock. Over the past few years, the company's organic revenue hasn't been increasing at a particularly impressive rate. The drugmaker
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Vertex Pharmaceuticals (NASDAQ: VRTX) has churned out nice profits quarter after quarter for years. The big biopharmaceutical company's cystic fibrosis (CF) franchise made it easy.
However, Vertex
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Vertex Pharmaceuticals (NASDAQ: VRTX) has churned out nice profits quarter after quarter for years. The big biopharmaceutical company's cystic fibrosis (CF) franchise made it easy.
However, Vertex
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Vertex Pharmaceuticals (NASDAQ: VRTX) has churned out nice profits quarter after quarter for years. The big biopharmaceutical company's cystic fibrosis (CF) franchise made it easy.
However, Vertex
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
Johnson & Johnson (NYSE: JNJ) is one of the top healthcare companies in the world. Last year, it spun off its consumer health business to focus on growing other parts of its operations, which